Summit Therapeutics (SMMT) Change in Cash (2019 - 2026)

Summit Therapeutics has reported Change in Cash for 8 years, with the latest figure at -$118.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 211.34% year-over-year to -$118.8 million; the trailing twelve-month figure through Mar 2026 stood at -$105.0 million (down 169.9% YoY), and the FY2025 full-year result was $120.4 million, up 256.6% from the prior year.
• Change in Cash for Q1 2026 stood at -$118.8 million, down from -$13.3 million in the prior quarter.
• The five-year high for Change in Cash was $526.6 million in Q4 2022, with the low at -$577.6 million in Q1 2023.
• Historically, Change in Cash has averaged $2.1 million across 5 years, with a median of -$9.8 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Cash jumped 6327.22% — and 2023, when it slumped 10307.42%.
• Summit Therapeutics' Change in Cash stood at $526.6 million in 2022, then slumped by 90.96% to $47.6 million in 2023, then sank by 76.72% to $11.1 million in 2024, then tumbled by 219.88% to -$13.3 million in 2025, then slumped by 793.33% to -$118.8 million in 2026.
• The last three Change in Cash figures came in at -$118.8 million (Q1 2026), -$13.3 million (Q4 2025), and -$59.3 million (Q3 2025), per Business Quant data.